Marking a proud moment for Indian science, the Central Research Institute in Kasauli unveiled its domestically manufactured Tetanus and Adult Diphtheria (TD) vaccine, with Union Health Minister JP Nadda presiding over the inaugural ceremony. This first-of-its-kind launch advances India’s quest for vaccine sovereignty.
Nadda praised the CRI’s innovation as a landmark for public health resilience, reflecting the Modi government’s push for self-dependence. Achieving 99 percent immunization coverage, this vaccine elevates India’s global health profile dramatically.
By April 2026, CRI aims to deliver 55 lakh doses under the national program, with production set to expand. States are aligning with PM Modi’s blueprint, turning ambitions into reality in pharmaceuticals and wellness.
As the world’s pharmacy with top-tier WHO recognition, India’s feats stand out. Nadda recalled prolonged historical developments versus COVID’s swift success: two vaccines in months, billions of digital doses administered.
The TD vaccine targets adult vulnerabilities, enhancing nationwide protection. This step not only secures supplies but also inspires global vaccine ecosystems, affirming India’s innovative edge.